Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart.

  • Ghigo, Alessandra
  • Ameri, Pietro
  • Asnani, Aarti
  • Bertero, Edoardo
  • de Boer, Rudolf A
  • Farmakis, Dimitrios
  • González, Arantxa
  • Heymans, Stephane
  • Ibáñez, Borja
  • López-Fernández, Teresa
  • Lyon, Alexander R
  • Pollesello, Piero
  • Rakisheva, Amina
  • Stellos, Konstantinos
  • Streckfuss-Bömeke, Katrin
  • Tocchetti, Carlo Gabriele
  • Thum, Thomas
  • van der Meer, Peter
  • Van Rooij, Eva
  • Ponikowski, Piotr
  • Metra, Marco
  • Rosano, Giuseppe
  • Van Linthout, Sophie
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the implementation of effective treatments. Therefore, there is a crucial need for appropriate preclinical models to understand the biological basis of their cardiotoxicity. This scientific statement summarizes the preclinical models hitherto used, from in vitro two- and three-dimensional human systems to small and large animals, to pinpoint the molecular mechanisms behind the cardiotoxicity of new-generation anticancer therapies, particularly immunotherapies, and to develop potential cardioprotective strategies. Furthermore, it discusses how preclinical models have contributed to the provocative concept of heart failure being potentially tumorigenic and how the discovery of drugs with both anticancer and cardioprotective actions has revealed a common mechanistic basis for heart failure and cancer. Finally, it discusses the existing gaps between preclinical models and clinical observations in patients, how these discrepancies affect regulatory pathways and the drug development process in cardio-oncology and provides recommendations for closing these gaps.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

  • de Boer, Rudolf A..
  • Hulot, Jean-Sébastien
  • Tocchetti, Carlo Gabriele|||0000-0001-5983-688X
  • Aboumsallem, Joseph Pierre
  • Ameri, Pietro|||0000-0001-7167-7287
  • Anker, Stefan|||0000-0002-0805-8683
  • Bauersachs, Johann|||0000-0002-9341-117X
  • Bertero, Edoardo
  • Coats, Andrew J. S.
  • Čelutkienė, Jelena
  • Chioncel, O.|||0000-0002-3197-3628
  • Dodion, Pierre
  • Eschenhagen, Thomas
  • Farmakis, Dimitrios|||0000-0001-8364-3447
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Jäger, Dirk
  • Jankowska, Ewa A.
  • Kitsis, Richard N.
  • Konety, Suma H.
  • Larkin, James
  • Lehmann, Lorenz
  • Lenihan, Daniel J.
  • Maack, Christoph
  • Moslehi, Javid J.
  • Müller, Oliver J.
  • Nowak-Sliwinska, Patrycja
  • Piepoli, Massimo Francesco
  • Ponikowski, Piotr|||0000-0002-3391-7064
  • Pudil, Radek
  • Rainer, Peter P.|||0000-0002-2840-6454
  • Ruschitzka, Frank
  • Sawyer, Douglas
  • Seferovic, Petar M.
  • Suter, Thomas
  • Thum, Thomas|||0000-0003-4360-1511
  • van der Meer, Peter|||0000-0002-9705-4413
  • Van Laake, Linda W.
  • von Haehling, Stephan
  • Heymans, Stephane
  • Lyon, Alexander R.
  • Backs, Johannes|||0000-0002-2322-2699
The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as each disease interferes with the treatment of the other. In addition to shared risk factors, a growing body of experimental and clinical evidence reveals numerous commonalities in the biology underlying both pathologies. Inflammation emerges as a common hallmark for both diseases as it contributes to the initiation and progression of both HF and cancer. Under stress, malignant and cardiac cells change their metabolic preferences to survive, which makes these metabolic derangements a great basis to develop intersection strategies and therapies to combat both diseases. Furthermore, genetic predisposition and clonal haematopoiesis are common drivers for both conditions and they hold great clinical relevance in the context of personalized medicine. Additionally, altered angiogenesis is a common hallmark for failing hearts and tumours and represents a promising substrate to target in both diseases. Cardiac cells and malignant cells interact with their surrounding environment called stroma. This interaction mediates the progression of the two pathologies and understanding the structure and function of each stromal component may pave the way for innovative therapeutic strategies and improved outcomes in patients. The interdisciplinary collaboration between cardiologists and oncologists is essential to establish unified guidelines. To this aim, pre-clinical models that mimic the human situation, where both pathologies coexist, are needed to understand all the aspects of the bidirectional relationship between cancer and HF. Finally, adequately powered clinical studies, including patients from all ages, and men and women, with proper adjudication of both cancer and cardiovascular endpoints, are essential to accurately study these two pathologies at the same time. We describe the co-occurrence of cancer and heart failure (HF), their potential shared risk factors, and their pathophysiological mechanisms. We advocate intense interaction between cardiologists and oncologists to achieve unifying hypotheses and collaborative pre-clinical and clinical studies.